{"id":"placebo-to-cms","safety":{"commonSideEffects":[]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Placebo serves as the control arm in phase 3 clinical trials to establish efficacy and safety of an investigational drug by comparison. It contains no active pharmaceutical ingredient and relies on the placebo effect and natural disease progression to establish a baseline for comparison against the active treatment arm.","oneSentence":"This is a placebo control used in clinical trials and does not have an active pharmaceutical mechanism.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:28:43.880Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[]},"trialDetails":[{"nctId":"NCT07471698","phase":"PHASE1, PHASE2","title":"hiPSC-CMs-loaded Chitosan Patch to Treat Severe Chronic Ischemic Heart Disease","status":"NOT_YET_RECRUITING","sponsor":"Help Therapeutics","startDate":"2026-10-20","conditions":"Ischemic Heart Failure, CABG-patients","enrollment":16},{"nctId":"NCT07402369","phase":"PHASE2","title":"Phase II Study of CMS-D002 Capsule for Uterine Fibroids With Menorrhagia","status":"RECRUITING","sponsor":"Shenzhen Kangzhe Biotechnology Co., Ltd.","startDate":"2026-02-19","conditions":"Uterine Fibroids With Menorrhagia","enrollment":120},{"nctId":"NCT07465120","phase":"PHASE2","title":"A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase Ⅱ Clinical Study to Evaluate the Efficacy and Safety of CMS-D001 in Adult Patients With Moderate to Severe Atopic Dermatitis","status":"NOT_YET_RECRUITING","sponsor":"Dermavon Holdings Limited","startDate":"2026-03-20","conditions":"Moderate to Severe Atopic Dermatitis","enrollment":160},{"nctId":"NCT07462780","phase":"PHASE1","title":"A Phase I Clinical Trial to Evaluate CMS-D017 Following Single and Multiple Doses in Healthy Participants","status":"NOT_YET_RECRUITING","sponsor":"Shenzhen Kangzhe Biotechnology Co., Ltd.","startDate":"2026-03","conditions":"Paroxysmal Nocturnal Hemoglobinuria, PNH, Complement-mediated Kidney Disease","enrollment":88},{"nctId":"NCT07432854","phase":"PHASE2, PHASE3","title":"A Clinical Study Evaluating the Efficacy and Safety of CMS-D001 Tablets in the Treatment of Adult Patients With Moderate to Severe Plaque-type Psoriasis","status":"NOT_YET_RECRUITING","sponsor":"Dermavon Holdings Limited","startDate":"2026-03-03","conditions":"Moderate to Severe Plaque Psoriasis","enrollment":540},{"nctId":"NCT06436742","phase":"PHASE1","title":"A Phase 1b Study to Investigate Safety and Tolerability of ARGX-119 in Adult Participants With DOK7-Congenital Myasthenic Syndromes (CMS)","status":"RECRUITING","sponsor":"argenx","startDate":"2024-09-24","conditions":"Congenital Myasthenic Syndrome, CMS","enrollment":16},{"nctId":"NCT04925453","phase":"NA","title":"tDCS and Cognitive Training in Active Duty Service Members With Mild TBI: A Pilot Study","status":"COMPLETED","sponsor":"United States Naval Medical Center, San Diego","startDate":"2021-01-19","conditions":"Brain Concussion, Brain Trauma, Attention Concentration Difficulty","enrollment":56},{"nctId":"NCT06834971","phase":"NA","title":"Colistin Methanesulfonate Sodium Inhalation for Prophylaxis of Ventilator-Associated Pneumonia (CIVAP): A Prospective, Multicentre, Double-Blind, Randomized, Placebo-Controlled Trial","status":"RECRUITING","sponsor":"Qilu Hospital of Shandong University","startDate":"2025-07-15","conditions":"Ventilator-Associated Pneumonia (VAP)","enrollment":508},{"nctId":"NCT01611896","phase":"NA","title":"Selenium Supplementation Versus Placebo in Patients With Graves' Hyperthyroidism","status":"COMPLETED","sponsor":"Rigshospitalet, Denmark","startDate":"2012-10","conditions":"Graves' Hyperthyroidism","enrollment":431},{"nctId":"NCT03460704","phase":"PHASE3","title":"Trial in Non-cystic Fibrosis Bronchiectasis Patients With Chronic Lung Infections Treated With Colistimethate Sodium.","status":"TERMINATED","sponsor":"Zambon SpA","startDate":"2018-01-29","conditions":"Non Cystic Fibrosis Bronchiectasis","enrollment":287},{"nctId":"NCT03093974","phase":"PHASE3","title":"Efficacy and Safety of Inhaled CMS in Bronchiectasis Subjects With Chronic P. Aeruginosa Infection. (PROMIS-I)","status":"COMPLETED","sponsor":"Zambon SpA","startDate":"2017-06-06","conditions":"Non Cystic Fibrosis Bronchiectasis","enrollment":377},{"nctId":"NCT04623632","phase":"PHASE2","title":"Effect of TAP Block on Time Required for First Analgesic Dose After Cesarean Cection Under Spinal Anesthesia","status":"COMPLETED","sponsor":"Ain Shams Maternity Hospital","startDate":"2020-09-20","conditions":"Postoperative Pain","enrollment":60},{"nctId":"NCT02562066","phase":"PHASE3","title":"Amifampridine Phosphate for the Treatment of Congenital Myasthenic Syndromes","status":"COMPLETED","sponsor":"Catalyst Pharmaceuticals, Inc.","startDate":"2016-01","conditions":"Myasthenic Syndromes, Congenital","enrollment":20},{"nctId":"NCT02963935","phase":"PHASE3","title":"Effect and Safety of Liraglutide 3.0 mg as an Adjunct to Intensive Behaviour Therapy for Obesity in a Non-specialist Setting","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2017-02-06","conditions":"Metabolism and Nutrition Disorder, Obesity","enrollment":282},{"nctId":"NCT02911818","phase":"PHASE4","title":"Lifestyle Modification and Liraglutide","status":"COMPLETED","sponsor":"University of Pennsylvania","startDate":"2016-09","conditions":"Obesity","enrollment":150},{"nctId":"NCT02452047","phase":"PHASE3","title":"Efficacy and Safety of Imipenem+Cilastatin/Relebactam (MK-7655A) Versus Colistimethate Sodium+Imipenem+Cilastatin in Imipenem-Resistant Bacterial Infection (MK-7655A-013)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2015-08-21","conditions":"Bacterial Infections","enrollment":50},{"nctId":"NCT01449838","phase":"PHASE1","title":"Phase I Study of Colistin Methanesulfonate Sodium","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2010-10-23","conditions":"Infections, Pseudomonas","enrollment":22},{"nctId":"NCT00952302","phase":"NA","title":"Study of the Effects of Iron Levels on the Lungs at High Altitude","status":"COMPLETED","sponsor":"University of Oxford","startDate":"2008-10","conditions":"Pulmonary Hypertension, Mountain Sickness","enrollment":33}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":218,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Placebo to CMS","genericName":"Placebo to CMS","companyName":"Merck Sharp & Dohme LLC","companyId":"merck-sharp-dohme-llc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":true,"score":2}}